<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Inhibitor</th><th>Target</th><th>Source</th><th>Final concentration</th></tr></thead><tbody><tr><td>Blebbistatin</td><td>Myosin II</td><td>Caymann Chemical</td><td>50 &#956;M</td></tr><tr><td>CK666</td><td>ARP2/3</td><td>Merck</td><td>50 &#956;M</td></tr><tr><td>Latrunculin A</td><td>Actin polymerisation</td><td>Merck</td><td>2 &#956;M</td></tr><tr><td>P505-15</td><td>SYK</td><td>BioVision</td><td>10 &#956;M</td></tr><tr><td>Para-Nitroblebbistatin</td><td>Myosin II</td><td>Optopharma</td><td>50 &#956;M</td></tr><tr><td>PP2</td><td>SRC-family kinases</td><td>Merck</td><td>50 &#956;M</td></tr><tr><td>SMIFH2</td><td>Formins</td><td>Merck</td><td>20 &#956;M</td></tr></tbody></table></table-wrap>